Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
Key facts
- Who runs it
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Where
- El Paso, Fort Bragg, Pittsburgh, and Tacoma, United StatesSee the 4 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 404 people, planned
- Started
- 19 Jul 2022
- Expected to end
- 19 May 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Erenumab 140 Mg/mL Subcutaneous Solution
- Placebo
- Record updated
- 22 February 2024
Who can take part
- Age
- 18 years to 50 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Male or female ≥18 and ≤50 years of age
- mTBI from any cause including impact, rotational acceleration, blast, or a combination, has occurred within the prior 7 days
- PTH has occurred within the prior 7 days
- Able to provide informed consent
- Likely to stay in the same geographical area for the duration of study
- Has a personal health care provider for standard of care PTH and TBI, including education, diagnostic procedures including neuroimaging and treatment, as deemed clinically indicated by the health care provider
Who cannot take part
- Participants with ongoing chronic migraine or other chronic daily headache disorders at the time of injury
- Sustained a moderate or severe TBI, rather than mTBI, indicated with at least 1 of the following associated with head injury:; abnormal structural imaging; loss of consciousness for >30 minutes; alteration of consciousness/mental state for >24 hours 3. post-traumatic amnesia for >1 day
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
This trial is currently available in United States.
- William Beaumont Army Medical CenterEl Paso, United StatesContact: Cecilia Valdovinos, NPTaking people
- Womack Army Medical Center - Fort LibertyFort Bragg, United StatesContact: Jennifer Robles, RNTaking people
- University of Pittsburgh Concussion Research LaboratoryPittsburgh, United StatesContact: Courtney PerryNot yet recruiting
- Madigan Army Medical CenterTacoma, United StatesContact: Janel CuevasNot yet recruiting
About the trial
What the trial wants to find out
This study aims to assess the effect and safety of erenumab compared to placebo for the treatment of acute posttraumatic headache (PTH) in military service members and civilians with mild traumatic brain injury (mTBI).
The 2 groups in the trial
- Active DrugTreatment being tested
Erenumab administered once monthly via two 70-mg subcutaneous injections at 3 time points over a 12-week period.
Treatment: Erenumab 140 Mg/mL Subcutaneous Solution
- PlaceboPlacebo, for comparison
Placebo administered once monthly via two subcutaneous injections at 3 time points over a 12-week period.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Treatment of Acute Post-Traumatic Headache With Erenumab 140 mg, Military Service Members and Civilians With Mild TBI: A Randomized, Double Blind, Placebo Controlled, Multicenter 12-week Duration Study Followed by a 4-week Open-Label Safety Extension
- Criteria questions
- Built from NCT05049057, who can take part
- Record updated
- 22 February 2024